![IJMS | Free Full-Text | IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis IJMS | Free Full-Text | IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis](https://www.mdpi.com/ijms/ijms-23-00555/article_deploy/html/images/ijms-23-00555-g001-550.jpg)
IJMS | Free Full-Text | IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis
![Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study - Iversen - Journal of the European Academy of Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study - Iversen - Journal of the European Academy of](https://onlinelibrary.wiley.com/cms/asset/bcfb3331-79cd-4c90-9f48-0bc9bb8f4153/jdv18846-fig-0001-m.jpg)
Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study - Iversen - Journal of the European Academy of
![JCM | Free Full-Text | Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan JCM | Free Full-Text | Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan](https://www.mdpi.com/jcm/jcm-10-05732/article_deploy/html/images/jcm-10-05732-g001.png)
JCM | Free Full-Text | Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
![PDF) Complete Skin Clearance and PASI response rates in clinical practice‐ Predictors, Health Related Quality of Life improvements and implications for treatment goals PDF) Complete Skin Clearance and PASI response rates in clinical practice‐ Predictors, Health Related Quality of Life improvements and implications for treatment goals](https://i1.rgstatic.net/publication/334591204_Complete_Skin_Clearance_and_PASI_response_rates_in_clinical_practice-_Predictors_Health_Related_Quality_of_Life_improvements_and_implications_for_treatment_goals/links/5d76732d299bf1cb8094d292/largepreview.png)
PDF) Complete Skin Clearance and PASI response rates in clinical practice‐ Predictors, Health Related Quality of Life improvements and implications for treatment goals
![Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin - Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin -](https://onlinelibrary.wiley.com/cms/asset/c2bba42f-92ad-4571-a063-e47457dca6d0/bjd20971-fig-0001-m.jpg)
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin -
![Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA) | Scientific Reports Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA) | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-18790-9/MediaObjects/41598_2022_18790_Fig1_HTML.png)
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA) | Scientific Reports
![IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - ScienceDirect IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0091674919306827-fx1.jpg)
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - ScienceDirect
![IJMS | Free Full-Text | Biological Mechanisms of Paeonoside in the Differentiation of Pre-Osteoblasts and the Formation of Mineralized Nodules IJMS | Free Full-Text | Biological Mechanisms of Paeonoside in the Differentiation of Pre-Osteoblasts and the Formation of Mineralized Nodules](https://www.mdpi.com/ijms/ijms-22-06899/article_deploy/html/images/ijms-22-06899-g001.png)
IJMS | Free Full-Text | Biological Mechanisms of Paeonoside in the Differentiation of Pre-Osteoblasts and the Formation of Mineralized Nodules
![Biomedicines | Free Full-Text | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center Biomedicines | Free Full-Text | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center](https://www.mdpi.com/biomedicines/biomedicines-10-01058/article_deploy/html/images/biomedicines-10-01058-g001-550.jpg)